How much ongoing smoking reduction is echoes of the initial mass education?

This is the first simulation model described in the text of the paper "How much ongoing smoking reduction is echoes of the initial mass education?" . The simulation needs to be run in Netlogo (https://ccl.northwestern.edu/netlogo/)Conflict of interest disclosure statement This study was conducted as part of a wider programme of research being undertaken by the Centre of Research Excellence: Indigenous Sovereignty & Smoking. The funding for that programme of work was obtained following submission of a researcher-initiated application for a funding grant from the Foundation for a Smoke-Free World, Inc. ("FSFW"), a US non-profit 501(c)(3) private foundation. This study is, under the terms of the grant agreement with FSFW, editorially independent of FSFW. The contents, selection and presentation of facts, as well as any opinions expressed herein, are the sole responsibility of the authors and under no circumstances should they be regarded as reflecting the positions of FSFW. Neither the authors nor the Centre of Research Excellence: Indigenous Sovereignty & Smoking have any commercial interests in vaping, snus, oral nicotine or tobacco products. CVP has a corpus of past work that challenges specific claims that particular anti-smoking interventions are effective. During the course of his career, CVP has received research grants, salary, or consulting fees from almost everyone with a financial interest in the sale of tobacco products, including national and state/provincial governments of the U.S. and Canada, manufacturers of cigarettes, vaping, snus, and other tobacco products, pharmaceutical companies, and insurance companies, as well as advocacy organizations attempting to eliminate use of these products, advocacy organizations attempting to defend consumers' rights to choose these products, and publishers who focus on these products. His only such funding during his work on this project came from the aforementioned grant in support of this project. M.G. has, over 10 years ago, received fees from pharmaceutical companies for consultancy re cessation medicine